Valaciclovir: A review of its use in the management of herpes zoster

Drugs

Volumn 59, Issue 6, 2000, Pages 1317-1340

  Ormrod, Douglas ^a   Karen, Goa ^a  

^a ADIS INTERNATIONAL LIMITED   (New Zealand)

Author keywords

[No Author keywords available]

Indexed keywords

ACICLOVIR; ACICLOVIR DERIVATIVE; ANTACID AGENT; CIMETIDINE; DIGOXIN; DNA POLYMERASE; FAMCICLOVIR; PENCICLOVIR; PROBENECID; THIAZIDE DIURETIC AGENT; THYMIDINE KINASE; VALACICLOVIR;

ANTIVIRAL ACTIVITY; CLINICAL TRIAL; DOSE RESPONSE; DRUG ABSORPTION; DRUG BLOOD LEVEL; DRUG COST; DRUG DISTRIBUTION; DRUG ELIMINATION; DRUG MECHANISM; DRUG METABOLISM; DRUG TOLERABILITY; HEADACHE; HERPES ZOSTER; HERPES ZOSTER OPHTHALMICUS; HUMAN; NAUSEA; PAIN; QUALITY OF LIFE; REVIEW; TREATMENT OUTCOME; VARICELLA ZOSTER VIRUS;

DNA VIRUSES; GEOCORIS; HERPES; HERPES ZOSTER; HERPESVIRIDAE; HUMAN HERPESVIRUS 3;

EID: 0034100079     PISSN: 00126667     EISSN: None     Source Type: Journal    
DOI: 10.2165/00003495-200059060-00009     Document Type: Review

References (94)

1. 1. McCrary ML, Severson J, Tyring SK. Varicella zoster virus. J Am Acad Dermatol 1999 Jul; 41: 1-14
2. 2. Lee BW. Review of varicella zoster seroepidemiology in India and Southeast Asia. Trop Med Int Health 1998; 3 (11): 886-90
3. 3. Schmader K. Management of herpes zoster in elderly patients. Infect Dis Clin Pract 1995; 4 (4): 293-9
4. 4. Gilden DH, Vafai A, Shtram Y, et al. Varicella-zoster virus DNA in human sensory ganglia. Nature 1983; 306: 478-80
5. 5. Nikkels AF, Piérard GE. Recognition and treatment of shingles. Drugs 1994 Oct; 48: 528-48
6. 6. Rogers RS, Tindall JP. Herpes zoster in the elderly. Postgrad Med 1971 Dec; 50 (6): 153-7
7. 7. Beutner KR, Friedman DJ, Forszpaniak C, et al. Valaciclovir compared with acyclovir for improved therapy for herpes zoster in immunocompetent adults. Antimicrob Agents Chemother 1995 Jul; 39: 1546-53
8. 8. Dworkin RH, Boon RJ, Griffin DRG, et al. Postherpetic neuralgia: impact of famciclovir, age, rash severity, and acute pain in herpes zoster patients. J Infect Dis 1998; 178 Suppl. 1: S76-80
9. 9. Liesegang TJ. Corneal complications from herpes zoster ophthalmicus. Ophthalmology 1985; 92 (3): 316-24
10. 10. Liesegang TJ. Varicella-zoster virus eye disease. Cornea 1999; 18 (5): 511-31
11. 11. Johnson RW. Herpes zoster and postherpetic neuralgia: optimal treatment. Drugs Aging 1997 Feb; 10: 80-94
12. 12. Hanania MM, Brietstein D. Postherpetic neuralgia: a review. Cancer Invest 1997; 15 (2): 165-76
13. 13. Bean B, Braun C, Balfour Jr HH. Acyclovir for acute herpes zoster. Lancet 1982; 2: 118-21
14. 14. van den Broek PJ, van der Meer JWM, Mulder JD, et al. Limited value of acyclovir in the treatment of uncomplicated herpes zoster: a placebo-controlled study. Infection 1984; 12: 338-41
15. 15. Crooks RJ, Jones DA, Fiddian AP. Zoster-associated chronic pain: an overview of clinical trials with acyclovir. Scand J Infect Dis 1991 Suppl. 78: 62-88
16. 16. Wood MJ, Kay R, Dworkin RH, et al. Oral acyclovir therapy accelerates pain resolution in patients with herpes zoster: a meta-anamysis of placebo-controlled trials. Clin Infect Dis 1996; 22: 341-7
17. 17. Jackson JL, Gibbons R, Meyer G, et al. The effect of treating herpes zoster with oral acyclovir in preventing postherpetic neuralgia - a meta-analysis. Arch Intern Med 1997 Apr 28; 157: 909-12
18. 18. Looke DFM. Revisiting herpes zoster - updating management. Mod Med Aust 1999; 42 (4): 67-78
19. 19. Perry CM, Faulds D. Valaciclovir: a review of its antiviral activity, pharmacokinetic properties and therapeutic efficacy in herpesvirus infections. Drugs 1996 Nov; 52: 754-72
20. 20. Ormrod DJ, Scott LJ, Perry CM. Valaciclovir: a review of its long term utility in the management of genital herpes simplex virus and cytomegalovirus infections. Drugs 2000; 59 (4): 839-63
21. 21. Griffiths P. Update on herpesvirus infections. J R Coll Physicians Lond 1998; 32 (3): 199-202
22. 22. Cohen JI, Brunell PA, Straus SE, et al. Recent advances in varicella-zoster virus infection. Ann Intern Med 1999; 130 (11): 922-32
23. 23. Beutner KR. Valacyclovir: a review of its antiviral activity, pharmacokinetic properties, and clinical efficacy. Antiviral Res 1995; 28 (4): 281-90
24. 24. Wagstaff AJ, Faulds D, Goa KL. Aciclovir: a reappraisal of its antiviral activity, pharmacokinetic properties and therapeutic efficacy. Drugs 1994; 47 (1): 153-205
25. 25. Patel R. Valaciclovir: development, clinical utility and potential. Expert Opin Invest Drugs 1997; 6 (2): 173-89
26. 26. Glaxo Wellcome. Valtrex (valacyclovir hydrochloride) caplets. Product information. 1999, Research Triangle Park (NC)
27. 27. Takahashi K, Suzuki M, Iwata Y, et al. Selective activity of various nucleoside and nucleotide analogues against human herpesvirus 6 and 7. Antiviral Chem Chemother 1997; 8 (1): 24-31
28. 28. Kedes DH, Ganem D. Sensitivity of Kaposi's sarcoma-associated herpesvirus replication to antiviral drugs: implications for potential therapy. J Clin Invest 1997; 99 (9): 2082-6
29. 29. Medveczky MM, Horvath E, Lund T, et al. In vitro antiviral drug sensitivity of the Kaposi's sarcoma-associated herpesvirus. AIDS 1997; 11: 1327-32
30. 30. Neyts J, de Clercq E. Antiviral drug susceptibility of human herpesvirus 8. Antimicrob Agents Chemother 1997; 41 (12): 2754-6
31. 31. Ertl P, Snowden W, Lowe D, et al. A comparative study of the in vitro and in vivo antiviral activities of acyclovir and penciclovir. Antiviral Chem Chemother 1995; 6 (2): 89-97
32. 32. Champness JN, Bennett MS, Wein F, et al. Exploring the active site of herpes simplex virus type-1 thymidine kinase by X-ray crystallography of complexes with aciclovir and other ligands. Proteins 1998; 32 (3): 350-61
33. 33. Reusser P. Herpesvirus resistance to antiviral drugs: a review of the mechanisms, clinical importance and therapeutic options. J Hosp Infect 1996 Aug; 33: 235-48
34. 34. Boivin G, Edelman K, Pedneault L, et al. Phenotypic and genotypic characterization of acyclovir-resistant varicella-zoster virus isolates from persons with AIDS. J Infect Dis 1994; 170: 68-95
35. 35. Morfin F, Thouvenot D, de Tourenne-Tessier M, et al. Phenotypic and genetic characterization of thymidine kinase from clinical strains of varicella-zoster virus resistant to acyclovir. Antimicrob Agents Chemother 1999; 43 (10): 2412-6
36. 36. Reusser P, Cordonnier C, Einsele H, et al. European survey of herpesvirus resistance to antiviral drugs in bone marrow transplant recipients. Bone Marrow Transplant 1996; 17: 813-7
37. 37. Ida M, Kageyama S, Sato H, et al. Emergence of resistance to acyclovir and penciclovir in varicella-zoster virus and genetic analysis of acyclovir-resistant variants. Antiviral Res 1999; 40: 155-66
38. 38. Snoeck R, Andrei G, De Clercq E. Current pharmacological approaches to the therapy of varicella zoster virus infections: a guide to treatment. Drugs 1999 Feb; 57: 187-206
39. 39. Wetherall NT, Hodges-Savola CA, Reyes M, et al. Acyclovir-resistant herpes simplex virus: characterization of virus isolates from a nationwide surveillance system [abstract no. 17]. Antiviral Res 1998; 37 (3): A44
40. 40. Soul-Lawton J, Weller S, On N, et al. Oral valaciclovir - increased acyclovir bioavailability in different patient populations [abstract no. P59]. AIDS 1994 Nov; 8 Suppl. 4: S33
41. 41. Azuma J, Yamamoto I, Aoki T, et al. A phase I study of a new antiviral drug, valaciclovir hydrochloride (256U87), in healthy male volunteers [in Japanese]. Rinsho Iyaku 1998; 14 (15): 2683-700
42. 42. Weller S, Blum MR, Doucette M, et al. Pharmacokinetics of the acyclovir pro-drug valaciclovir after escalating single-and multiple-dose administration to normal volunteers. Clin Pharmacol Ther 1993 Dec; 54: 595-605
43. 43. Soul-Lawton J, Seaber E, On N, et al. Absolute bioavailability and metabolic disposition of valaciclovir, the 1-valyl ester of acyclovir, following oral administration to humans. Antimicrob Agents Chemother 1995 Dec; 39: 2759-64
44. 44. de Miranda P, Blum MR. Pharmacokinetics of acyclovir after intravenous and oral administration. J Antimicrob Chemother 1983; 12 Suppl. B: 29-37
45. 45. Crooks RJ. Valaciclovir - a review of its potential in the management of genital herpes. Antiviral Chem Chemother 1995; 6 Suppl. 1: 39-44
46. 46. First MR, Blum MR, Brennan P, et al. Pharmacokinetics (PK) of 256U87, an acyclovir (ACV) prodrug in renal transplant (RTX) patients [abstract]. Clin Pharmacol Ther 1993 Feb; 53: 238
47. 47. Wang LH, Schultz M, Weller S, et al. Pharmacokinetics and safety of multiple-dose valaciclovir in geriatric volunteers with and without concomitant diuretic therapy. Antimicrob Agents Chemother 1996 Jan; 40: 80-5
48. 48. Jacobson MA, Gallant J, Wang LH, et al. Phase I trial of valaciclovir, the 1-valyl ester of acyclovir, in patients with advanced human immunodeficiency virus disease. Antimicrob Agents Chemother 1994 Jul; 38: 1534-40
49. 49. Conant MA, Murphy R, Thompson S, et al. Valaciclovir for the management of recurrent herpes simplex virus infection in HIV-infected individuals - two double-blind controlled trials. London: Glaxo Wellcome, 1999 (Data on file)
50. 50. On NT, Ehninger G, Gluckman E, et al. Acyclovir pharmacokinetics following oral multiple-dose of valaciclovir (Valtrex) in allogeneic BMT patients [abstract]. Bone Marrow Transplant 1995 Mar; 15 Suppl. 2: S122
51. 51. Burnette TC, Harrington JA, Reardon JE, et al. Purification and characterization of a rat liver enzyme that hydrolyzes valaciclovir, the 1-valyl ester prodrug of acyclovir. J Biol Chem 1995; 270 (26): 15827-31
52. 52. De Bony F, Bidault R, Tod M, et al. Interaction of cimetidine and probenecid with valaciclovir and its metabolite acyclovir [abstract]. 36th ICAAC 1996 Sep: New Orleans, LA 15: 6
53. 53. Glaxo Wellcome. Valtrex. Summary of product characteristics. Greenford: Glaxo Wellcome, 1999
54. 54. Glaxo Wellcome K.K. Antiviral chemotherapeutic agent. Valtrex Tablets 500. Tokyo: Glaxo Wellcome, 2000
55. 55. Smiley ML, The International Valaciclovir Zoster Study Group. The efficacy and safety of valaciclovir for the treatment of herpes zoster. 33rd International Conference on Antimicrobial Agents and Chemotherapy. 1993 Oct 17-20; New Orleans (LA), 340
56. 56. Johnson RW, Crooks RJ, International Valaciclovir Zoster Study Group. The clinical efficacy of valaciclovir in the treatment of herpes zoster [abstract]. J Eur Acad Dermatol Venerol 1995 Oct; 5 Suppl. 1: S75
57. 57. Niimura M, Honda M, Kawashima M, et al. Early phase II study of valaciclovir hydrochloride tablet in patients with herpes zoster [in Japanese]. Rinsho Iyaku 1998; 14 (15): 2701-15
58. 58. Niimura M, Honda M, Nishikawa T, et al. Late phase II study of valaciclovir hydrochloride tablet in patients with herpes zoster: optimal dose finding by double-blind comparative study [in Japanese]. Rinsho Iyaku 1998; 14 (16): 2833-66
59. 59. Tagami H, Okuyama R, Funayama M, et al. Clinical efficacy of valaciclovir hydrochloride tablet in patients with herpes zoster: open study [in Japanese]. Rinsho Iyaku 1998; 14 (16): 2903-20
60. 60. Niimura M, Honda M, Nishikawa T, et al. Phase III study of valaciclovir hydrochloride tablets in patients with herpes zoster: double-blind comparative study with aciclovir tablets [in Japanese]. Rmsho Iyaku 1998; 14 (16): 2867-902
61. 61. Decroix J, Partsch H, Gonzalez R, et al. Factors influencing pain outcomes in herpes zoster - an observational study with valaciclovir. J Eur Acad Dermatol Venerol 2000; 14 (1): 23-33
62. 62. Severson J, Tyring S, Evans T, et al. Efficacy and safety of oral valacyclovir (VACV) 1.5MG [1.5g in text] BID in the treatment of acute herpes zoster [abstract]. 57th Annual Meeting of the Americal Acadamy of Dermatology; 1999 Mar 19-24; New Orleans (LA), 36
63. 63. Colin J, Prisant O, Cochener B, et al. A double-blind randomized trial to compare the efficacy and safety of valaciclovir and aciclovir for the treatment of herpes zoster ophthalmicus. Ophthalmology. In press
64. 64. Grant DM, Mauskopf JA, Bell L, et al. Comparison of valaciclovir and acyclovir for the treatment of herpes zoster in immunocompetent patients over 50 years of age: a cost-consequence model. Pharmacotherapy 1997 Mar-Apr; 17: 333-41
65. 65. Whitley RJ, Shukla S, Crooks RJ, et al. The identification of risk factors associated with persistent pain following herpes zoster. J Infect Dis 1998; 178 Suppl. 1: S71-5
66. 66. Wood MJ, Shukla S, Fiddian AP, et al. Treatment of acute herpes zoster: effect of early (<48 h) versus late (48-72 h) therapy with acyclovir and valaciclovir on prolonged pain. J Infect Dis 1998 Nov; 178 Suppl. 1: S81-4
67. 67. Van der Straten M, Carrasco D, Lee P, et al. Comparison of valacyclovir and famciclovir for treatment of acute herpes zoster [abstract no. 374]. Poster Book, American Academy of Dermatology, 58th Annual Meeting: 2000 Mar 10-15, San Francisco (CA)
68. 68. Wood MJ, Herpes Zoster CTCG. How should zoster trials be conducted? J Antimicrob Chemother 1995 Dec; 36: 1089-101
69. 69. Dworkin RH, Carrington D, Cunningham A, et al. Assessment of pain in herpes zoster: lessons learned from antiviral trials. Antiviral Res 1997; 33: 73-85
70. 70. Wood MJ, Ogan PH, McKendrick MW, et al. Efficacy of oral acyclovir in the treatment of herpes zoster. Am J Med 1988; 85 Suppl. 2A: 79-83
71. 71. Mahalingam R, Wellish M, Wolf W, et al. Latent varicella-zoster viral DNA in human trigeminal and thoracic ganglia. N Engl J Med 1990; 323 (10): 627-31
72. 72. Cobo LM, Foulks GN, Liesegang T, et al. Oral acyclovir in the treatment of acute herpes zoster ophthalmicus. Ophthalmology 1996; 93 (6): 763-70
73. 73. Hoang-Xuan T, Büchi ER, Herbort CP, et al. Oral acyclovir for herpes zoster ophthalmicus. Ophthalmology 1992; 99 (7): 1062-71
74. 74. Harding SP, Porter SM. Oral acyclovir in herpes zoster ophthalmicus. Curr Eye Res 1991; 10 Supp.: 177-82
75. 75. Choo PW, Galil K, Donahue JG, et al. Risk factors for postherpetic neuralgia. Arch Intern Med 1997 Jun 9; 157: 1217-24
76. 76. Meister W, Neiß A, Gross G, et al. A prognostic score for postherpetic neuralgia in ambulatory patients. Infection 1998; 26 (6): 359-63
77. 77. Grose C, Wiedeman J. Generic acyclovir vs. famciclovir and valacyclovir. Pediatr Infect Dis J 1997; 16 (9): 838-41
78. 78. Tilson HH, Engle CR, Andrews EB. Safety of acyclovir: a summary of the first 10 years experience. J Med Virol 1993; 41 Suppl. 1: 67-73
79. 79. Bodsworth NJ, Crooks RJ, Borelli S, et al. Valaciclovir versus aciclovir in patient initiated treatment of recurrent genital herpes: a randomised, double blind clinical trial. Genitourin Med 1997; 73: 110-6
80. 80. Spruance SL, Tyring SK, DeGregorio B, et al. A large-scale placebo-controlled, dose-ranging trial of peroral valaciclovir for episodic treatment of recurrent herpes genitalis. Arch Intern Med 1996 12/26 Aug; 156: 1729-35
81. 81. Tyring SK, Douglas Jr JM, Corey L, et al. A randomized, placebo-controlled comparison of oral valacyclovir and acyclovir in immunocompetent patients with recurrent genital herpes infections. Arch Dermatol 1998 Feb; 134: 185-91
82. 82. Fife KH, Barbarash RA, Rudolph T, et al. Valaciclovir versus acyclovir in the treatment of first-episode genital herpes infection: results of an international, multicenter, double-blind, randomized clinical trial. Sex Transm Dis 1997 Sep; 24: 481-6
83. 83. Conlon CP. Herpes zoster. Prescr J 1995; 35 (2): 46-52
84. 84. Höglund M, Ljungman P, Larsson R, et al. Comparable aciclovir exposures produced by oral valaciclovir and intravenous aciclovir in immunocompromised cancer patients [abstract no. P7]. J Antimicrob Chemother 1999; 44 Suppl. A: 42
85. 85. Donahue JG, Choo PW, Manson JE, et al. The incidence of herpes zoster. Arch Intern Med 1995 7/12 Aug; 155: 1605-9
86. 86. VZV Research Foundation. The Varicella-Zoster Virus & VZV Infections. Available from: http://www.vzvfoundation.org/ templates/VaricellaZosterVirus.cfm [Accessed 2 May 2000]
87. 87. Wood MJ. Herpes zoster in immunocompetent patients. Res Clin Forum 1986; 8 (6): 61-8
88. 88. Stein GE. Pharmacology of new antiherpes agents: famciclovir and valacyclovir. Both of these prodrugs produce higher plasma concentrations of active antiviral agent than is observed with oral acyclovir. J Am Pharm Assoc 1997; 37 (2): 157-63
89. 89. Hong W, Cousins M. Postherpetic neuralgia: is it preventable and treatable? Mod Med Aust 1996; 39 (3): 84-7
90. 90. Johnson R, Mandal B, Bowsher D, et al. Guidelines for the management of shingles: report of a Working Group of the British Society for the Study of Infection. J Infect 1995; 30: 193-200
91. 91. Wood MJ, Kroon S, editors. Management strategies in herpes: reducing the burden of zoster-associated pain - update. 2nd ed. Worthing: PPS Europe, 1997
92. 92. Wood MJ, Kroon S, on behalf of the International Herpes Management Forum. Reducing the burden of zoster-associated pain - update. Available from: URL: http://www.ihmf.com/library/libpost.asp [Accessed 20 May 2000]
93. 93. Tyring S, Barbarash RA, Nahlik JE, et al. Famciclovir for the treatment of acute herpes zoster: effects on acute disease and postherpetic neuralgia: a randomised, double blind placebo-controlled trial. Ann Intern Med 1995; 123: 89-96
94. 94. Degreef H, Famciclovir Herpes Zoster Clinical Study Group. Famiciclovir, a new oral antiherpes drug: results of the first controlled clinical study demonstrating its efficacy and safety in the treatment of uncomplicated herpes zoster in immunocompetent patients. Int J Antimicrob Agents 1994; 4: 241-6